The fully automated chemiluminescent immunoassay is used for quantitative determination of VWF collagen-binding activity in human citrated plasma to determine von Willebrand Disease (VWD).
Testing of VWD is simplified with HemosIL AcuStar and it gives out faster and more accurate results.
The company claims that the HemosIL AcuStar is the first and only automated von Willebrand Factor (VWF) collagen-binding activity solution in Hemostatis testing.
HemosIL AcuStarVWF:CB expands the assay panel and creates a complete panel for primary investigation of VWD.
Other assays in HemosIL AcuStar VWF include HemosIL AcuStar VWF Antigen (VWF:Ag) and HemosIL AcuStar VWF Ristocetin Cofactor (VWF:RCo) Activity.
HemosIL AcuStar VWF:CB is ready to use and cartridge-based and can give out results in less than 30 minutes, on demand 24/7. It says that chemiluminescence offers improved linearity range to quantify extremely low levels of VWF concentrations and provides superior performance and reliability compared to ELISA methods.
IL Worldwide Hemostasis Marketing director Remo Tazzi said: "HemosIL AcuStar VWF:CB expands our VWF Assay Panel to provide clinicians with a broader diagnostic picture, plus faster, more reliable results.
"Enhanced sensitivity improves accuracy while automation of complex assays expedites turnaround time. This not only enables better patient management, but also means more efficient testing."
VWD is generally classified into three categories which include partial quantitative deficiency (type 1), complete quantitative deficiency (type 3) and functional deficiency (type 2). Type 2 VWD can be further categorised into subtypes based on functional deficiency present (Type 2A, 2B, 2M, and 2N).
